Hepatic Artery Infusion Chemotherapy for Liver Malignancy

Leal, Julie N.; Kingham, T. Peter

doi:10.1016/j.soc.2014.09.005

Cited by 21 publications

(8 citation statements)

References 77 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatic artery infusion (HAI) chemotherapy allows precise delivery of high‐dose regional hepatic chemotherapy. Taking advantage of the anatomic dependence of metastatic liver tumors on hepatic arterial blood supply, HAI chemotherapy effectively delivers a high‐concentration of drug to the liver disease, and minimizes any adverse effect on normal parenchyma . 5‐fluoro‐2‐deoxyuridine (FUDR) is a particularly suitable chemotherapeutic drug for intrahepatic delivery, with a high first‐pass hepatic extraction of 94‐99% .…”

Section: Introductionmentioning

confidence: 99%

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

Pak

Kemeny

Capanu

et al. 2017

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

Pak

Kemeny

Capanu

et al. 2017

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In such cases, sclerosis of the bile ducts is hypothesized to occur in response to a combination of drug toxicity and microvascular ischemia. Because the bile ducts are dependent on the hepatic artery for blood supply, they are particularly at risk from arterial infusion of cytotoxic agents (12). The addition of systemic bevacizumab to intra-arterial floxuridine infusion may increase the risk of biliary complications (67), although biliary sclerosis associated with intravenous bevacizumab administration alone without intra-arterial floxuridine has also been reported (68).…”

Section: Cholangitis and Biliary Strictures-bili-mentioning

confidence: 99%

Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis

et al. 2018

View full text Add to dashboard Cite

Human cancers are genetically complex and diverse. Although advances in oncologic therapy aim to define and target unique steps in carcinogenesis, oncologists often rely on less discriminate anticancer therapies that have consequences for normal tissues. Even many of the so-called targeted therapies currently employed can adversely affect normal cells, leading to complications that necessitate dose reductions or cessation of specific therapies. This article explores the unintended consequences of currently employed systemic and ablative anticancer therapies that might manifest at imaging examinations of the abdomen and pelvis, including cytotoxic, molecular targeted, and immunologic agents; ablation; and hematopoietic stem cell transplant. Each of these treatments can have both major and minor unintended effects in the targeted organ(s), in local or adjacent structures, or at distant sites. Timely detection and reporting of adverse consequences of anticancer therapies by the astute imager can result in critical treatment modifications and/or lifesaving interventions; therefore, knowledge of these unintended effects is paramount for radiologists interpreting the results of imaging examinations in cancer patients. RSNA, 2018.

show abstract

“…Since liver tumors obtain their nutrient blood supply from the hepatic artery[ 176 ], hepatic artery infusion- (HAI) supported chemotherapy has been applied for the treatment of both primary and metastatic liver cancers in patients and shown to be an effective treatment for unresectable advanced HCC[ 177 ]. Effectiveness of this intervention relates to the concentration of chemotherapeutics in HCCs by direct delivery to the tumors, with limited systemic exposure in the liver[ 178 ].…”

Section: Introductionmentioning

confidence: 99%

Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer

Suresh¹,

Menne²

2021

WJGO

View full text Add to dashboard Cite

This review describes woodchucks chronically infected with the woodchuck hepatitis virus (WHV) as an animal model for hepatocarcinogenesis and treatment of primary liver cancer or hepatocellular carcinoma (HCC) induced by the hepatitis B virus (HBV). Since laboratory animal models susceptible to HBV infection are limited, woodchucks experimentally infected with WHV, a hepatitis virus closely related to HBV, are increasingly used to enhance our understanding of virus-host interactions, immune response, and liver disease progression. A correlation of severe liver pathogenesis with high-level viral replication and deficient antiviral immunity has been established, which are present during chronic infection after WHV inoculation of neonatal woodchucks for modeling vertical HBV transmission in humans. HCC in chronic carrier woodchucks develops 17 to 36 mo after neonatal WHV infection and involves liver tumors that are comparable in size, morphology, and molecular gene signature to those of HBV-infected patients. Accordingly, woodchucks with WHV-induced liver tumors have been used for the improvement of imaging and ablation techniques of human HCC. In addition, drug efficacy studies in woodchucks with chronic WHV infection have revealed that prolonged treatment with nucleos(t)ide analogs, alone or in combination with other compounds, minimizes the risk of liver disease progression to HCC. More recently, woodchucks have been utilized in the delineation of mechanisms involved in innate and adaptive immune responses against WHV during acute, self-limited and chronic infections. Therapeutic interventions based on modulating the deficient host antiviral immunity have been explored in woodchucks for inducing functional cure in HBV-infected patients and for reducing or even delaying associated liver disease sequelae, including the onset of HCC. Therefore, woodchucks with chronic WHV infection constitute a well-characterized, fully immunocompetent animal model for HBV-induced liver cancer and for preclinical evaluation of the safety and efficacy of new modalities, which are based on chemo, gene, and immune therapy, for the prevention and treatment of HCC in patients for which current treatment options are dismal.

show abstract

Hepatic Artery Infusion Chemotherapy for Liver Malignancy

Cited by 21 publications

References 77 publications

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential

Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis

Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer

Contact Info

Product

Resources

About